Lopinavir concentrations in cerebrospinal fluid exceed the 50% inhibitory concentration for HIV

AIDS

Volumn 19, Issue 9, 2005, Pages 949-952

  Capparelli, Edmund V ^a   Holland, Diane ^a   Okamoto, Charles ^a   Gragg, Bryan ^a   Durelle, Janis ^a   Marquie Beck, Jennifer ^a   Van Den Brande, Geoffrey ^a   Ellis, Ron ^a   Letendre, Scott ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cerebrospinal fluid; HIV; Inhibitory concentration; Lopinavir; Pharmacokinetics; Plasma

Indexed keywords

ANTIRETROVIRUS AGENT; LOPINAVIR; PLASMA PROTEIN;

ADULT; ARTICLE; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 20644464770     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.aids.0000171409.38490.48     Document Type: Article

References (12)

1. Beach JW. Chemotherapeutic agents for human immunodeficiency virus infection: mechanism of action, pharmacokinetics, metabolism, and adverse reactions. Clin Ther 1998; 20:2-25.
2. Enting RH, Hoetelmans RM, Lange JM, Burger DM, Beijnen JH, Portegies P. Antiretroviral drugs and the central nervous system. AIDS 1998; 12:1941-1955.
3. Aweeka F, Jayewardene A, Staprans S, Bellibas SE, Kearney B, Lizak P, et al. Failure to detect nelfinavir in the cerebrospinal fluid of HIV-1-infected patients with and without AIDS dementia complex. J Acquir Immune Defic Syndr Hum Retrovirol 1999; 20:39-43.
4. Letendre SL, Capparelli EV, Ellis RJ, McCutchan JA. Indinavir population pharmacokinetics in plasma and cerebrospinal fluid. The HIV Neurobehavioral Research Center Group. Amimicrob Agents Chemother 2000; 44:2173-2175.
5. Kravcik S, Gallicano K, Roth V, Cassol S, Hawley-Foss N, Badley A, et al. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 1999; 21:371-375.
6. Anon. ABT-378/r Investigator's Manual. Abbott Park, IL: Abbott Laboratories; 2 May 2000.
7. van Praag RM, Weverling GJ, Portegies P, Jurriaans S, Zhou XJ, Turner-Foisy ML, et al. Enhanced penetration of indinavir in cerebrospinal fluid and semen after the addition of low-dose ritonavir. AIDS 2000; 14:1187-1194.
8. Haas DW, Johnson B, Nicotera J, Bailey VL, Harris VL, Bowles FB, et al. Effects of ritonavir on indinavir pharmacokinetics in cerebrospinal fluid and plasma. Antimicrob Agents Chemother 2003; 47:2131.
9. Lafeuillade A, Solas C, Halfon P, Chadapaud S, Hittinger G, Lacarelle B. Differences in the detection of three HIV-1 protease inhibitors in non-blood compartments: clinical correlations. HIV Clin Trials 2002; 3:27-35.
10. Cvetkovic RS, Goa KL. Lopinavir/ritonavir: a review of its use in the management of HIV infection. Drugs 2003; 63:769-802.
11. Solas C, Lafeuillade A, Halfon P, Chadapaud S, Hittinger C, Lacarelle B. Discrepancies between protease inhibitor concentrations and viral load in reservoirs and sanctuary sites in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 2003; 47:238-243.
12. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ. Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrobial Agents Chemother 2004; 48:437-443.